[Federal Register Volume 75, Number 206 (Tuesday, October 26, 2010)]
[Notices]
[Pages 65667-65668]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-27026]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Lincoln Pharmacy; Revocation of Registration
On March 26, 2010, I, the Deputy Administrator of the Drug
Enforcement Administration, issued an Order to Show Cause and Immediate
Suspension of Registration (Order) to Lincoln Pharmacy (Respondent), of
Edison, New Jersey. The Order proposed the revocation of Respondent's
DEA Certificate of Registration, BL4082222, and the denial of any
pending applications to renew or modify its registration, on the ground
that Respondent's ``continued registration is inconsistent with the
public interest.'' Order at 1 (citing 21 U.S.C. 823(f) & 824(a)(4)).
The Order alleged that Respondent ``routinely filled fraudulent
prescriptions for highly addictive and abused controlled substances''
and therefore violated 21 U.S.C. 841(a)(1) and 21 CFR 1306.04. Id. More
specifically, the Order alleged that Respondent had filled six
fraudulent prescriptions for Roxicodone and oxycodone, which are
schedule II controlled substances, in exchange for cash on multiple
occasions to wit: (1) On January 14, 2010, it filled three
prescriptions totaling 540 dosage units of Roxicodone (30 mg.) for $975
in cash; (2) on January 21, 2010, it filled one prescription totaling
120 dosage units of oxycodone (30 mg.) for $215 in cash; and (3) on
January 28, 2010, it filled two prescriptions totaling 360 tablets of
oxycodone for $650 in cash. Id. at 1-2.
Based on the above, I concluded that Respondent's ``continued
registration during the pendency of these proceedings would constitute
an imminent danger to the public health and safety.'' Id. at 2. I
therefore exercised my authority under 21 U.S.C. 824(d) and immediately
suspended Respondent's registration. Id.
On April 6, 2010, the Order, which also notified Respondent of its
right to request a hearing on the allegations or to submit a written
statement in lieu of a hearing, the procedures for doing so, and the
consequence of failing to do so, was served on it. Id. at 2-3 (citing
21 CFR 1301.43(a), (c), (d) & (e)). Since that time, neither
Respondent, nor anyone purporting to represent it, has either requested
a hearing or submitted a written statement in lieu of a hearing. Thirty
days now having passed since the Order was served on Respondent, I
conclude that Respondent has waived its right to a hearing. See 21 CFR
1301.43(b) & (d). I therefore issue this Decision and Final Order based
on the evidence contained in the investigative record submitted by the
Government. Id. 1301.43(e). I make the following findings.
Findings
Respondent is a retail pharmacy located at 52 Lincoln Highway,
Edison, New Jersey, which is owned and operated by Mr. Vincent Hsia, a
registered pharmacist. Respondent is the holder of Certificate of
Registration, BL4082222, which authorizes it to dispense controlled
substances in schedules II through V as a retail pharmacy. Respondent's
registration does not expire until March 31, 2012.
On January 14, 2010, at shortly after 7 p.m., a cooperating source
(CS) went to Respondent and presented three prescriptions to Mr. Hsia.
Each of the prescriptions was for 180 tablets of Roxicodone (oxycodone)
30 mg., contained dosing instructions, stated ``chronic intractable
pain,'' and was signed. While it is unclear whether the prescriptions
the CS presented contained a patient name, the evidence which includes
three cash-register receipts, the vials and the drugs, shows that at
approximately 7:17 through 7:22 p.m., Hsia delivered the three vials,
each containing 180 tablets of Roxicodone 30 mg. (for a total of 540
tablets), to the CS and charged him $325 in cash for each vial for a
total of $975. The prescriptions listed the patients as Chris DiMarco
of Clark, NJ; Rudy Lore, also purportedly of Clark; and Paul Smith of
Rahway, NJ.
On January 21, 2010, at 7:45 p.m., the CS returned to Respondent
and presented a prescription for 180 tablets of oxycodone 30 mg. This
prescription listed the patient as Michael Williams of Newark, NJ.
According to the transcript of a recording of the CS's conversation
with Mr. Hsia, at one point the CS asked: ``Quick questions. Since I'm
moving [expletive deleted] moving these things really fast, is there
any way you could write for more than 180? There isn't, right?'' Hsia
replied: ``I don't really even like filling for 180.'' The CS then
mentioned that an associate had told him that ``you could get 240 all
the time or somethin[g].'' Hsia replied: ``I can't even give you 180. I
have to give you 120. Cause it doesn't say chronic intractable pain.''
Hsia subsequently distributed 120 tablets of oxycodone 30 mg. to the
CS.
On January 27, 2010, the CS called Hsia to ask him what phrase
needed to be on the prescription to justify dispensing the larger
quantity. Hsia told him ``chronic intractable pain.'' The following
day, the CS returned to Respondent and presented two more prescriptions
for 180 tablets of oxycodone 30 mg. which appear to have included the
notation of ``chronic intractable pain.'' One of the prescriptions
listed the patient as Paul Fusatola of Belleville, NJ; the other as
Rachel Billis of Nutley, NJ. The CS paid $325 in cash for each
prescription and Hsia distributed two vials, each containing 180
tablets of oxycodone 30 mg., to the CS.
Discussion
Section 304(a) of the Controlled Substances Act provides that ``[a]
registration * * * to * * * dispense a controlled substance * * * may
be suspended or revoked by the Attorney General upon a finding that the
registrant * * * has committed such acts as would render his
registration under section 823 of this title inconsistent with the
public interest as determined under such section.'' 21 U.S.C.
824(a)(4). In determining the public interest in the case of a
practitioner, the Act directs that the Attorney General consider the
following factors:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The applicant's experience in dispensing * * * controlled
substances.
[[Page 65668]]
(3) The applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id. Sec. 823(f).
``[T]hese factors are * * * considered in the disjunctive.'' Robert
A. Leslie, M.D., 68 FR 15227, 15230 (2003). I may rely on any one or a
combination of factors, and may give each factor the weight I deem
appropriate in determining whether a registration should be revoked
and/or an application should be denied. Id. Moreover, it is well
settled that I am ``not required to make findings as to all of the
factors.'' Hoxie v. DEA, 419 F.3d 477, 482 (6th Cir. 2005); see also
Morall v. DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005). However, the
Government has the burden of proof. 21 CFR 1301.44(d) & (e).
Having considered all of the factors, I conclude that the evidence
pertinent to factors two and four makes out a prima facie showing that
Respondent ``has committed such acts as would render [its] registration
* * * inconsistent with the public interest.'' 21 U.S.C. 824(a)(4).
Accordingly, Respondent's registration will be revoked and any pending
applications will be denied.
Factors Two and Four--Respondent's Experience in Dispensing Controlled
Substances and Compliance With Applicable Laws Relating to Controlled
Substances
Under a longstanding DEA regulation, a prescription for a
controlled substance is unlawful unless it has been ``issued for a
legitimate medical purpose by an individual practitioner acting in the
usual course of his professional practice.'' 21 CFR 1306.04(a). The
regulation further provides that while ``[t]he responsibility for the
proper prescribing and dispensing of controlled substances is upon the
prescribing practitioner, * * * a corresponding responsibility rests
with the pharmacist who fills the prescription.'' Id. (emphasis added).
Continuing, the regulation states that ``the person knowingly filling
such a purported prescription, as well as the person issuing it, [is]
subject to the penalties provided for violations of the provisions of
law relating to controlled substances.'' Id.
DEA has consistently interpreted this provision as prohibiting a
pharmacist from filling a prescription for a controlled substance when
he either ``knows or has reason to know that the prescription was not
written for a legitimate medical purpose.'' Medic-Aid Pharmacy, 55 FR
30043, 30044 (1990); see also Frank's Corner Pharmacy, 60 FR 17574,
17576 (1995); Ralph J. Bertolino, 55 FR 4729, 4730 (1990); United
States v. Seelig, 622 F.2d 207, 213 (6th Cir. 1980). This Agency has
further held that ``[w]hen prescriptions are clearly not issued for
legitimate medical purposes, a pharmacist may not intentionally close
his eyes and thereby avoid [actual] knowledge of the real purpose of
the prescription.'' Bertolino, 55 FR at 4730 (citations omitted).\1\
---------------------------------------------------------------------------
\1\ As the Supreme Court recently explained, ``the prescription
requirement * * * ensures patients use controlled substances under
the supervision of a doctor so as to prevent addiction and
recreational abuse. As a corollary, [it] also bars doctors from
peddling to patients who crave the drugs for those prohibited
uses.'' Gonzales v. Oregon, 546 U.S. 243, 274 (2006) (citing United
States v. Moore, 423 U.S. 122, 135 (1975)).
---------------------------------------------------------------------------
The evidence here shows that on multiple occasions, Respondent
violated Federal law by dispensing prescriptions for oxycodone 30 mg.,
a schedule II controlled substance (see 21 CFR 1308.12(b)), which Mr.
Hsia, its owner and pharmacist in charge, knew were not ``issued for a
legitimate medical purpose'' by a ``practitioner acting in the usual
course of his professional practice.'' Id. 1306.04(a); see also 21
U.S.C. 841(a)(1) (``Except as authorized by this subchapter, it shall
be unlawful for any persons knowingly or intentionally * * * to
distribute[] or dispense * * * a controlled substance.'').
More specifically, the evidence shows that on January 14, 2010, a
CS simultaneously presented three prescriptions, each for 180 tablets
of Roxicodone (oxycodone) 30 mg., to Hsia. Hsia then proceeded to fill
the prescriptions and distributed the drugs to the CS from whom he
received $975 in cash. Hsia clearly knew that the prescriptions were
unlawful as the CS presented all three prescriptions (all of which for
the same drug and quantity) at the same time and Hsia used three
different patient names (Chris DeMarco, Rudy Lore and Paul Smith) on
the prescription labels so as to hide the fact (in the event he was
inspected) that he had distributed the drugs to a single person. In
short, Hsia knowingly engaged in a drug deal. 21 U.S.C. Sec.
841(a)(1).
The evidence further shows that on January 21, 2010, Hsia again
unlawfully distributed 120 tablets of oxycodone 30 mg. to the CS in
exchange for $215 in cash. Moreover, at the time the CS presented the
prescription (which was in the name of Michael Williams) to Hsia, the
CS told Hsia that he was re-selling the drugs, explaining that they
were ``moving these things really fast'' and asked if he could get more
than 180 tablets. While on this occasion Hsia only distributed 120
tablets to the CS (apparently because the prescription did not state
``chronic intractable pain''), he clearly knew that the CS was seeking
the drugs for an illegal purpose and not to treat a legitimate medical
condition. Hsia thus again violated 21 U.S.C. Sec. 841(a)(1).
Finally, on January 28, 2010, the CS presented two more
prescriptions to Hsia; the prescriptions listed two different persons
(Paul Fusatola and Rachel Billis) as the patients. Each prescription
was for 180 tablets of oxycodone 30 mg. and indicated that it was for
``chronic intractable pain.'' Hsia again distributed both prescriptions
to the CS from whom he received $650 in cash, knowing that the CS was
seeking the drugs for an illegal purpose. Hsia thus committed two
additional violations of the CSA by unlawfully distributing controlled
substances in violation of 21 U.S.C. Sec. 841(a)(1).
As the forgoing demonstrates, Respondent's owner Mr. Hsia has used
its registration to engage in blatant drug dealing. I therefore hold
that Respondent has committed multiple acts which render its
registration ``inconsistent with the public interest.'' 21 U.S.C.
824(a)(4). Accordingly, Respondent's registration will be revoked and
any pending application will be denied. For the same reasons that I
immediately suspended Respondent's registration, I conclude that public
interest requires that this Order be effective immediately.
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) &
824(a), as well as 28 CFR 0.100(b) & 0.104, I hereby order that DEA
Certificate of Registration, BL4082222, issued to Lincoln Pharmacy, be,
and it hereby is, revoked. I further order that any pending application
of Lincoln Pharmacy for renewal or modification of its registration be,
and it hereby is, denied. This Order is effective immediately.
Dated: October 15, 2010.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 2010-27026 Filed 10-25-10; 8:45 am]
BILLING CODE 4410-09-P